cancers-logo

Journal Browser

Journal Browser

Means of Improving Gastric Cancer Response to Chemotherapy and Immunotherapy

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1091

Special Issue Editors


E-Mail Website
Guest Editor
1. Surgical Department, Charité-Universitätsmedizin Berlin, Berlin, Germany
2. Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany
Interests: peritoneal malignancies; gastric cancer; complications

E-Mail Website
Guest Editor
Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Interests: oral anticancer agents; adherence; occupational exposure; reaction; hypothyroidism; pharmacist intervention; medication safety; oncology pharmacy; patient education; adverse effect management

Special Issue Information

Dear Colleagues,

Gastric cancer remains a major global health burden and despite advances in chemotherapy and immunotherapy, treatment response varies widely among patients. Primary resistance, acquired resistance, treatment-related toxicities and poor adherence continue to limit the effectiveness of systemic therapies. Therefore, identifying strategies to improve therapeutic response while maintaining safety and quality of life is an urgent clinical challenge.

This Special Issue focuses on multidisciplinary approaches to enhance gastric cancer response to chemotherapy and immunotherapy. Topics of interest include, but are not limited to, optimization of systemic therapy through pharmacological and clinical interventions, management of adverse events affecting treatment continuity, biomarkers predicting response or resistance and strategies to improve adherence to oral anticancer agents. Particular attention is given to real-world clinical research, pharmacist-led interventions and supportive care measures that enable patients to maintain treatment intensity and duration.

In addition, this Special Issue welcomes studies on immunotherapy-related adverse event management, combination strategies integrating chemotherapy and immunotherapy and innovative approaches to personalize treatment based on patient characteristics. By integrating clinical oncology, oncology pharmacy and supportive care perspectives, this Special Issue aims to provide practical insights that translate into improved treatment outcomes for patients with gastric cancer.

Prof. Dr. Beate Rau
Dr. Kazuo Kobayashi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • chemotherapy response
  • immunotherapy
  • treatment adherence
  • adverse event management
  • oncology pharmacy
  • pharmacist intervention
  • oral anticancer agents
  • medication safety

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 361 KB  
Review
Treatment Limitations and Missing Information in Peritoneal Metastatic Gastric Cancer
by Beate Rau, Franziska Köhler, Annika Kurreck, Safak Gül, Alexander Arnold, Uli Fehrenbach, Resa Puffert, Florian Lordick, Fabian Kockelmann and Thomas Wirth
Cancers 2026, 18(9), 1336; https://doi.org/10.3390/cancers18091336 - 22 Apr 2026
Viewed by 646
Abstract
Background/Objectives: Peritoneal metastasis represents the most frequent and prognostically unfavorable metastatic pattern in gastric cancer, largely due to limited sensitivity of conventional imaging, delayed diagnosis, and insufficient response assessment. The aim of this review is to provide an overview of the current [...] Read more.
Background/Objectives: Peritoneal metastasis represents the most frequent and prognostically unfavorable metastatic pattern in gastric cancer, largely due to limited sensitivity of conventional imaging, delayed diagnosis, and insufficient response assessment. The aim of this review is to provide an overview of the current evidence on the diagnosis and treatment of gastric cancer with peritoneal metastases and to address current treatment limitations and options. Methods: This review was designed as a narrative review and is based on an extensive literature search in established databases. Results: Systemic chemotherapy remains the cornerstone of palliative treatment, improving the survival and quality of life compared with the best supportive care; however, outcomes in peritoneally metastatic disease remain poor. Advances in molecularly targeted and immune-based therapies have extended survival in selected patient populations, yet favorable molecular profiles are mainly unknown in peritoneal metastases. Staging laparoscopy and semi-quantitative assessment using the Peritoneal Cancer Index (PCI) are therefore essential for accurate diagnosis, prognostication, and treatment selection. Growing evidence from retrospective studies, multi-institutional cohorts, and selected randomized trials suggests that a multimodal approach—combining systemic therapy with intraperitoneal or bidirectional chemotherapy—may improve survival and quality of life. In carefully selected patients whose primary gastric tumor and peritoneal lesions respond to systemic treatment, complete cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) may further enhance outcomes and, in rare cases, achieve long-term survival. These potential benefits appear to be limited to highly selected patients with a low peritoneal tumor burden (PCI ≤ 6–7), positive cytology, good performance status, controlled extraperitoneal disease, and a high likelihood of achieving complete macroscopic cytoreduction (CC-0). Conclusions: Although the treatment intent in metastatic gastric cancer remains primarily palliative, carefully selected patients with limited peritoneal metastases may benefit from intensified multimodal treatment strategies when managed in specialized centers. Interdisciplinary evaluation, accurate staging, and individualized treatment planning are essential to optimize outcomes in this challenging disease setting. Full article
Show Figures

Figure 1

Back to TopTop